Why C.H. Robinson Stock Was Sliding Again Today

C.H. Robinson (CHRW) shares fell another 4.3% today, extending a slide that began with an 11% drop yesterday after the company announced it will acquire RXO for roughly $3 billion.

The two-day move reflects investor pushback on how the deal is structured. CHRW plans to suspend share buybacks and take on new debt to fund the purchase. Both choices pull back capital return and add leverage at the same time.

Wall Street analysts at Bank of America and Evercore trimmed their price targets, pointing to capital dilution and deal timing. Neither downgraded: both kept buy-equivalent ratings. That split is notable. The analysts are marking down near-term value while still endorsing the long-term thesis.

Management's case rests on a specific hurdle. CHRW expects the deal to turn earnings accretive within nine months, but only if it achieves $300 million in synergies. Interpretation: the accretion timeline depends entirely on hitting that synergy figure, so any slippage would push out the payoff while the buyback suspension and added debt remain in place.

Combined, the two sessions show a market pricing execution risk ahead of any evidence of integration progress. RXO is the acquisition target at the center of the transaction.